PerfuseCell Cronus A/S
A/SActiveAdvertising protectionCVR 31606810Nørrelundvej 10, 2730 HerlevManufacture of medical and dental instruments and supplies· NACE 3250Est. 2008 · 18 years old— employeeshttps://www.perfusecell.com
Loading company…
Overview
PerfuseCell Cronus A/S is a Danish A/S based in Herlev, operating in the Manufacture of medical and dental instruments and supplies sector. Incorporated in 2008, the company reported a gross profit of DKK 20.5k in its latest annual filing.
Gross profit 2025
0M DKK
−97% vs 2024
EBITDA margin (of gross profit)
100.0 %
+136547% vs 2024
Net profit 2025
0M DKK
+982% vs 2024
Key ratios
See full ratios →Solidity ratioEquity ÷ Total assets × 100
46.9 %
AverageAround the average of companies in the same industry
20212025
Liquidity ratioCurrent assets ÷ Short-term debt
1.9×
AverageAround the average of companies in the same industry
20212025
Return on assets (ROA)Net profit ÷ Total assets × 100
1.1 %
AverageAround the average of companies in the same industry
20212025
EBITDA — year on year
DKK thousandsKey figures
Annual report 2025| Gross profit | 0M DKK | -97% |
| EBITDA | 0M DKK | +136547% |
| Net profit | 0M DKK | +982% |
| Total assets | 2.3M DKK | +51% |
| Equity | 1.1M DKK | +2% |
| Employees | — | — |
Company information
Legal name
PerfuseCell Cronus A/S
CVR number
31606810
Legal form
Aktieselskab
NACE code
Founded
1 July 2008 · 18 years
Share capital
DKK 500,000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktionen.
Company purpose
Selskabets formål er at drive industriel forsknings- og fremstillingsvirksomhed samt handel med udstyr til den farmaceutiske branche og hermed forbunden virksomhed.
(no translation available)
Contact
Address
Nørrelundvej 10, 2730 Herlev
Phone
+45 4411 5400
Email
info@perfusecell.com
Website
https://www.perfusecell.com
Advertising protection
Active — opted out of marketing use
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
Financial development
In its most recent annual report (2025), PerfuseCell Cronus A/S reported a gross profit of DKK 20.5k, a decrease of 97% on the year before. The figures on this page draw on 5 annual filings covering 2021 to 2025. The bottom line showed a net profit of DKK 24.0k, and the EBITDA margin stood at 100%.
At the end of 2025, equity financed 46.9% of the balance sheet, and current assets covered short-term debt 1.9 times.
Financials
Revenue
DKK thousandsEBITDA
DKK thousandsIncome statement
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 20 | 625 | 711 | 550 | 150 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 |
| EBITDA | 20 | -0 | 150 | 131 | 34 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 |
| EBIT | 20 | -0 | 150 | 131 | 34 |
| Net financials | 4 | 2 | 22 | 21 | 0 |
| Profit before tax | 24 | 2 | 171 | 152 | 34 |
| Tax | 0 | -0 | -0 | 63 | -0 |
| Net profit | 24 | 2 | 171 | 89 | 34 |
Get a credit rating – not just the numbers
Financial statements show the past. Risika gives you a score and a recommended credit limit, so you know what the numbers mean for your risk.
Balance sheet
DKK thousands| Item | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | 2,283 | 1,516 | 1,045 | 873 | 784 |
| Equity | 1,071 | 1,047 | 1,045 | 873 | 784 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 1,212 | 469 | 0 | 0 | 0 |
| Total debt | 1,212 | 469 | 0 | 0 | 0 |
Financial ratios
5-year trendEBITDA margin
100.0 %
20212025
Equity ratio
46.9 %
AverageAround the average of companies in the same industry
20212025
Return on equity
2.2 %
WeakAmong the 40% lowest rated companies in the industry
20212025
Net profit margin
117.1 %
20212025
Asset turnover
0.01×
20212025
Debt / equity
1.13×
AverageAround the average of companies in the same industry
20212025
Sector performance
22 of 28 ratios graded28 financial ratios from the latest filing, each graded against companies in the same industry.
Profitability
Return on equity (ROE)Weak
Among the 40% lowest rated companies in the industry
Net profit as a percentage of equity — the return the owners earned on their invested capital this year.
Return on assets (ROA)Average
Around the average of companies in the same industry
Net profit as a percentage of total assets — the return generated on the capital employed.
Return on net assets (RONA)Weak
Among the 40% lowest rated companies in the industry
Profit relative to net assets (total assets minus total debt) — the ability to generate earnings from the net asset base alone.
Basic earning power (BEP)Weak
Among the 40% lowest rated companies in the industry
EBIT relative to total assets — the company's earning power before the effects of tax and financial leverage.
Gross marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The gross result as a share of revenue — how much of the revenue is left after variable costs to cover the company's fixed costs.
Operating marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
EBIT as a share of revenue — the share of revenue remaining as earnings once all operating costs are covered. A key measure of earning power.
Net profit marginNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
The profit for the year as a share of revenue — the company's ability to turn revenue into profit.
Capacity ratioNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Shows how strongly fixed costs weigh on the gross result — a high ratio means fixed costs take only a small bite out of the earnings from basic operations.
Liquidity
Current ratioAverage
Around the average of companies in the same industry
Current assets relative to short-term debt — the ability to settle short-term obligations with current assets alone. Around 150% is considered satisfactory from a credit perspective.
Quick ratioStrong
Among the 40% highest rated companies in the industry
Current assets excluding inventory relative to short-term debt — whether the most liquid assets alone can cover the short-term obligations. A value of 1 or above signals a healthy liquidity position.
Cash ratioStrong
Among the 30% highest rated companies in the industry
Cash relative to short-term debt — the ability to repay short-term obligations with cash alone.
Current assets to equityWeak
Among the 30% lowest rated companies in the industry
Current assets relative to equity — an indicator of the balance-sheet structure and of the company's short- and long-term financing. The healthy level is highly industry-dependent.
Fixed assets to long-term capitalVery strong
Among the 10% highest rated companies in the industry
Fixed assets relative to long-term capital (equity plus long-term liabilities). Below 100% means the long-term capital finances more than just the fixed assets — a healthier liquidity position.
Cash conversion ratioWeak
Among the 30% lowest rated companies in the industry
Cash flow relative to profit — the ability to convert reported profits into accessible cash.
Debt & solvency
Solidity ratioAverage
Around the average of companies in the same industry
Equity as a share of total assets — the ability to absorb losses. Around 40% is considered satisfactory from a credit perspective.
Debt ratioAverage
Around the average of companies in the same industry
Total debt relative to the balance-sheet total — the share of the assets financed by debt rather than equity.
Debt to equityAverage
Around the average of companies in the same industry
Debt relative to equity — the company's leverage. A higher value means heavier reliance on debt financing.
Liabilities to equityAverage
Around the average of companies in the same industry
Total liabilities relative to equity — whether the company operates primarily on borrowed capital or on its own.
Income to debtAverage
Around the average of companies in the same industry
Profit relative to debt — the ability to create earnings while operating with debt.
EBITDA to debtWeak
Among the 40% lowest rated companies in the industry
EBITDA relative to debt — how much operating earnings are available to service the debt.
Interest coverageStrong
Among the 30% highest rated companies in the industry
The ability to pay the interest on the company's debt out of its earnings.
Interest rate on debtVery strong
Among the 20% highest rated companies in the industry
Financial expenses relative to total liabilities — the effective interest rate the company pays on its debt.
Interest marginAverage
Around the average of companies in the same industry
The return on assets minus the interest rate on debt. Positive means the company benefits from operating with debt; negative means the debt makes it worse off.
Efficiency & development
Equity to contributed capitalWeak
Among the 40% lowest rated companies in the industry
Total equity relative to the capital the owners contributed — how the equity has developed from its starting point.
One-year change in equityAverage
Around the average of companies in the same industry
The size of this year's increase or decrease in the company's equity.
One-year change in debtVery weak
Among the 10% lowest rated companies in the industry
The size of this year's increase or decrease in the company's debt.
Asset turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to total assets — the ability to generate revenue from the asset base.
Inventory turnoverNot rated
Cannot be graded — the figures this ratio builds on are not available in the latest filing.
Revenue relative to inventory — how many times a year the inventory is sold and replaced. A low value can indicate weak sales or excess inventory.
Annual reports & filings
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
People & ownership
Management
Actively employed in the business| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
FP Founder | Founder | 2008 |
PS Chief Executive Officer | Chief Executive Officer | 2025 |
Former (1)
NJ Management | Management | 2008 – 2015 |
Board of directors
Non-executive oversight| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
FP Board of Directors | Board of Directors | 2008 |
PS Board of Directors | Board of Directors | 2008 |
AK Board of Directors | Board of Directors | 2026 |
Former (2)
EJ Board of Directors | Board of Directors | 2008 – 2015 |
NJ Board of Directors | Board of Directors | 2008 – 2026 |
Shareholders
Active legal owners| Shareholder | Type | Ownership | Votes | Registered |
|---|---|---|---|---|
Stobbe GmbH | Company | 100% | 100% | 2022 |
| Company | 100% | 100% | 2015 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
One in three Danish companies experiences fraud
Sound familiar? See how to strengthen your defences and catch suspicious changes in ownership and management in time.
Related companies
Company hierarchy
Stobbe GmbH
PerfuseCell Cronus A/S Board network connections
Board members of PerfuseCell Cronus A/S also hold positions in 17 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Niels Johansen | Management | 11 companiesMany roles |
| Flemming Petersen | Founder | 2 companies |
| Erik Johansen | Board of Directors | 2 companies |
| Per Stobbe | Chief Executive Officer | 1 company |
| August Kisling Stobbe | Board of Directors | 1 company |
Frequently asked questions
What is the CVR number of PerfuseCell Cronus A/S?
PerfuseCell Cronus A/S is registered with CVR / Virk under CVR 31606810.
What is the gross profit of PerfuseCell Cronus A/S?
PerfuseCell Cronus A/S reported a gross profit of DKK 20.5k in 2025.
Who is the CEO of PerfuseCell Cronus A/S?
Per Stobbe is the CEO of PerfuseCell Cronus A/S, in role since 2025.
Where is PerfuseCell Cronus A/S headquartered?
PerfuseCell Cronus A/S's registered address is Nørrelundvej 10.